Ozgene Revenue and Competitors

Perth, WA aus

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Ozgene's estimated annual revenue is currently $12.1M per year.(i)
  • Ozgene's estimated revenue per employee is $155,000

Employee Data

  • Ozgene has 78 Employees.(i)
  • Ozgene grew their employee count by 53% last year.

Ozgene's People

NameTitleEmail/Phone
1
Chief Business Development OfficerReveal Email/Phone
2
Scientific Strategic PartneringReveal Email/Phone
3
Strategic PartneringReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$0.9M60%N/AN/A
#3
$5.1M336%N/AN/A
#4
$5.7M3742%N/AN/A
#5
$1.4M18-10%N/AN/A
#6
$3.7M48-21%$16MN/A
#7
$1.1M70%N/AN/A
#8
$0.8M5-81%N/AN/A
#9
$2.5M16-27%N/AN/A
#10
$0.8M5-17%N/AN/A
Add Company

What Is Ozgene?

Ozgene offers the full spectrum of capabilities to design, generate, breed & phenotype your mouse models.It was not that long ago that a mouse was just a mouse but, for the team at Ozgene, a mouse represents a way to advance humanity. Started 15 years ago, today, Ozgene is one of the leading companies providing genetically customised mice for researchers around the world. With best in industry timelines using their goGermline embryos other services include knock-in, knockout, humanized and transgenic mouse models, breeding and husbandry, validation and phenotyping and Geneoz VMS. Ozgene has developed a new goGermline approach, which is a revolutionary new technology to generate knockout and knock-in mice fast and efficiently, while improving animal welfare. Ozgene is now able to complete projects in less than 6 months. Whilst, Ozgene is an Australian company, 80% of their clients are located overseas and shipments leave the Ozgene facility almost daily for laboratories, small academic institutions, research institutes, biotechnology companies and multinational pharmaceutical companies in the US, Europe, Asia, South America and New Zealand. CEO and Co-founder, Dr Frank Koentgen, and the Ozgene team have over 20 years of experience in the generation of genetically modified mice. It begins even before Ozgene was born, when Dr Koentgen generated the first knockout mouse from the C57BL/6 mouse strain in 1993. Work has been published in scientific journals such as Cell, Nature, Science, Immunity, PNAS and Nature Medicine.

keywords:N/A

N/A

Total Funding

78

Number of Employees

$12.1M

Revenue (est)

53%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9.4M7826%N/A
#2
$9.6M80-13%N/A
#3
$19.6M8013%N/A
#4
$21.9M815%N/A
#5
$26.3M815%N/A